Triactol Research | Clinical Test Results

April 13th, 2012 by CJ | Posted under Others.

The emergence of Triactol™ Bust Serum is based on the result of several careful and systematic research studies

  • Numerous studies have demonstrated the safety and efficacy of Pueraria Mirifica.
  • Triactol is Dermatologically Tested- A total of 52 subjects completed the HRIPT (Human Repeat Insult Patch Test) study. No adverse reactions of any kind were reported during the course of this study.
  • No adverse reactions were recorded in 58 subjects who used Triactol™ Bust Serum in 2 in vivo clinical trials

Triactol Clinical Trial #1

Title: An open-label study was conducted to assess the efficacy & safety of Triactol™ Bust Serum among healthy female subjects.

  • All subjects were advised to apply Triactol™ Bust Serum twice daily
  • Results were taken via physical examination with interviews were gathered at day 0, day 21 (3 weeks) and day 42 (6 weeks)
  • At the final visit, questionnaires were administered to assess product safety and acceptance

1. Firming & Lifting Effects

triactol research firming and lifting Observations:

  • 75% of subjects experienced significant lifting and firming on day 21
  • Up to 94% of subjects experienced significant lifting and firming on day 42

2. Breast Enlargement Effect

Noticeable enlargement as early as 21 days of
application

At day 42,

  • 81% of the subjects experienced improvement in bust circumference
  • More than half (56%) of the subjects reported improvement to a cup size( 2cm) or more in 6 weeks

3. Product Acceptance & Others

Other important findings:

  • None of the subjects experienced any adverse reactions during this trial1
  • Reduction in wrinkle appearance & stretch marks on the bust area were reported
  • All of the subjects who tried other bust serums prefered Triactol™ Bust Serum1
  • 81% of the subjects experienced improved self confidence after using Triactol™ Bust Serum

Click HERE To Go To Triactol Product Page

Clinical Trial #2

Conducted by an independent 3rd party skin research centre (Data on File)
Objective: To evaluate the efficacy of Triactol™ on Bust Enlargement, Bust Firming and Bust Lifting

  • 42 subjects :Test group (20) and placebo group (22)
  • All subjects applied Triactol™ Bust Serum twice daily
  • Results were taken at the 3rd and 6th week
  • All data obtained were analysed using the paired t-test, ANCOVA and Chi-square test of the SPSS® 11.5 package programme

1.Breast Firming & Lifting

Significant improvements of bust angle and length observed in the test group after 3 weeks of bust serum application,
which was further enhanced after 6 weeks of bust serum application.

2.Breast Enlargement (Breast Volume)

triactol research breast volume

Change of the bust volume was analysed by 3D Image Analysis GFM PRIMOS body® (GFMesstechnik GmbH, Germany) at baseline and at 3-week intervals during the 6-week treatment period

  • Significant improvements were observed in the subjects using Triactol™ after 3 weeks of application and this was further enhanced after 6 weeks.
  • Mean size attained after 6 weeks is +119.92cc
  • The maximum size attained was +339.41cc after 6 weeks (bigger than a small (240 cc for 2 breasts) saline breast implant

3. Breast Enlargement (circumference)

  • Significant breast circumference improvement was observed in the test group, after 6 weeks of bust serum application.
  • Maximum improvement in breast circumference is up to 2.4cm.
  • Mean (average) improvement is 0.58cm.

triactol research circumference

4.Breast Elasticity

Test group experienced significant breast elasticity improvement compared with that of placebo, after 3 & 6 weeks of bust serum application.

Conclusion

The results of the in vivo instrumental assessments and self assessment studies demonstrated bust enlargement, bust firming and bust lifting after applying Triactol™ Bust Serum for 3-6 weeks.

No adverse events were reported during the course of the study!

Click HERE To Buy Triactol

Tags: , , , , , , , , , , , , , , ,

Comments are closed.